Alternative strategies

Carmignac Portfolio Merger Arbitrage Plus

Global marketArticle 8
Share Class

LU2585801256

An active absolute return strategy focusing on merger arbitrage opportunities
  • An active merger arbitrage strategy that aims to provide positive absolute returns, with limited correlation to equity markets.
  • An alternative strategy with a socially responsible investment approach, focusing on officially announced M&A deals in the developed markets.
  • Strategy offering positive correlation with interest rates.
Risk Indicator

1

2

3

4

5

6

7

Lowest risk Highest risk
Recommended Minimum Investment Horizon
3 years
Cumulative Performance since launch
+ 9.5 %
-
-
-
+ 4.8 %
From 14/04/2023
To 06/08/2025
Calendar Year Performance 2024
-
-
-
-
-
-
-
-
+ 2.8 %
+ 3.1 %
Net Asset Value
109.55 €
Asset Under Management
223 M €
Net Equity Exposure30/06/2025
83.6 %
SFDR - Fund Classification

Article

8
Data as of:  Aug 6, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Carmignac Portfolio Merger Arbitrage Plus fund performance

Take a look at the Fund's performance supported by our Fund managers’ market commentary and strategy insight.

Our monthly comments

Data as of:  Jul 31, 2025.
Fund management team

Market environment

• In a general context of renewed calm and confidence in the markets, the Merger Arbitrage strategy performed well in July. The HFRX Merger Arbitrage Index rose 0.86% in dollar terms over the month.• The tightening of spreads in July was driven by a stream of positive news. Firstly, the merger between Hess and Chevron was officially completed on July 18, 2025, marking the end of a process that began in October 2023. The merger had been significantly delayed by arbitration proceedings initiated by ExxonMobil concerning a right of first refusal on the Stabroek block in Guyana.
• Another significant development, in a context of easing tensions between China and the United States, the Chinese antitrust authorities approved the Ansys/Synopsis deal.
• On another note, bid improvements remain a positive trend. Olo, which accepted an offer from Thomas Bravo earlier this month, appears to have rejected a significantly higher offer from a third party. Chart Industries also benefited from an offer from Baker Hughes that was significantly higher than that of Flowserve.
• Finally, the completion of a large number of transactions led to an overall tightening of spreads.
• There were few negative surprises in July, the main one being the European Union's announcement of an in-depth investigation into the acquisition of Covestro by Abu Dhabi National Oil.
• M&A activity remained robust, with a surge in announcements at the end of the month.
• Mega-deals made a welcome return, with three transactions worth over $10 billion, including the takeover of Norfolk Southern by Union Pacific for more than $80 billion.
• A total of 26 new transactions were announced during the month. Private equity confirmed its active comeback, accounting for 22% of announced deals.

Performance commentary

• The fund posted a positive performance during the month.• The main positive contributors to performance were: HESS, Ansys and OLO.
• The main detractors from performance were: Covestro, Banca Generali and WNS.

Outlook strategy

• The fund's investment rate is 96%, down from the previous month following the completion of a number of transactions.• We will be able to reinvest the portfolio over the coming weeks thanks to new deals announced at the end of the month.
• With 52 positions in the portfolio, diversification remains satisfactory.
• 2025 continues to look much more promising than 2024 thanks to a more favourable antitrust environment for M&A activity worldwide: the change of administration in the US following Trump's election, the publication of the Draghi report in Europe recommending the emergence of national champions to face global competition, regulators in the UK being pushed by politicians to prioritise economic activity, and the Japanese market continuing to open up to foreign capital.
• Although instability linked to the Trump administration's trade war and geopolitical tensions slowed the recovery in the first half of the year, the announcements made at the end of July and the increasing number of bidding wars give us cause for optimism for the second half of the year.

Performance Overview

Data as of:  Aug 6, 2025.
​Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
Morningstar Rating™ :  © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Source: Carmignac at 08/08/2025

Carmignac Portfolio Merger Arbitrage Plus Portfolio overview

Below is an overview of the composition of the portfolio.

Geographical Breakdown

Data as of:  Jun 30, 2025.
North America50.2 %
Europe EUR12.9 %
Europe ex-EUR10.7 %
Others9.9 %
View details

Key figures

Below are the key figures for the Fund, which will give you a clearer idea of the Fund's management and equity positioning.

Exposure Data

Data as of:  Jun 30, 2025.
Net Equity Exposure83.6 %
Number of long strategies53
Merger arbitrage exposure106.3 %
Cash and other25.2 %

The strategy in a nutshell

Discover the Fund’s main features and benefits through the words of the Fund Managers.
Fund Management Team
The advantage of Merger Arbitrage strategy is that it carries virtually no market risk. The only associated risk is that of a deal failure. That is why our approach is very cautious on two levels: we’re very selective in choosing the deals and we aim to maintain a highly diversified portfolio.
View Fund's characteristics

Articles that may interest you

Alternative StrategyApril 14, 2025English

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

Find out more
Alternative StrategyJanuary 17, 2025English

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

Find out more
Alternative StrategyOctober 9, 2024English

Carmignac Merger Arbitrage: Letter from the Portfolio Managers

3 minute(s) read
Find out more
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice.
The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Carmignac Portfolio is a sub-fund of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive.
The information presented above is not contractually binding and does not constitute investment advice. Past performance is not a reliable indicator of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor), where applicable. Investors may lose some or all of their capital, as the capital in the UCI is not guaranteed. Access to the products and services presented herein may be restricted for some individuals or countries. Taxation depends on the situation of the individual. The risks, fees and recommended investment period for the UCI presented are detailed in the KIDs (key information documents) and prospectuses available on this website. The KID must be made available to the subscriber prior to purchase.). The reference to a ranking or prize, is no guarantee of the future results of the UCITS or the manager.